Compare AstraZeneca plc (AZN) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Freshworks Inc — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while Freshworks Inc trades at $11.66 (market cap $3.31B). The key difference: AstraZeneca plc is far larger — about 75× Freshworks Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| AZN | FRSH | |
|---|---|---|
Market Cap | $248.14B | $3.31B |
Sector | Health | Technology |
52-Week High | $209.48 | $13.97 |
52-Week Low | $147.06 | $6.88 |
Enterprise Value | $275.41B | $2.68B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Freshworks (FRSH) trades at $11.67, down 2.59% on the day, with a bullish technical signal from moving averages but a neutral RSI. The company reported strong Q2 2026 results, beating earnings estimates with $0.17 EPS, and achieved its first quarter of GAAP profitability in 2026. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience (EX) segment, which now represents 60% of ARR.
The outlook is positive, with a consensus price target of $16.50 implying significant upside. Key opportunities include AI monetization and public sector expansion via FedRAMP progress. Risks include high valuation multiples like a 40.22 EV/EBITDA and competitive pressure in the SaaS sector. Analyst sentiment is evenly split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
